- Home
- NBIX vs VTRS Comparison
NBIX vs VTRS Comparison
Compare NBIX & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- VTRS
- Stock Information
- Founded
- NBIX 1992
- VTRS 1961
- Country
- NBIX United States
- VTRS United States
- Employees
- NBIX N/A
- VTRS N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- NBIX Health Care
- VTRS Health Care
- Exchange
- NBIX Nasdaq
- VTRS Nasdaq
- Market Cap
- NBIX 11.0B
- VTRS 11.0B
- IPO Year
- NBIX 1996
- VTRS N/A
- Fundamental
- Price
- NBIX $87.58
- VTRS $7.36
- Analyst Decision
- NBIX Buy
- VTRS Hold
- Analyst Count
- NBIX 21
- VTRS 4
- Target Price
- NBIX $164.80
- VTRS $10.50
- AVG Volume (30 Days)
- NBIX 1.3M
- VTRS 16.1M
- Earning Date
- NBIX 04-30-2025
- VTRS 05-08-2025
- Dividend Yield
- NBIX N/A
- VTRS 6.52%
- EPS Growth
- NBIX 33.20
- VTRS N/A
- EPS
- NBIX 3.29
- VTRS N/A
- Revenue
- NBIX $2,355,300,000.00
- VTRS $14,739,300,000.00
- Revenue This Year
- NBIX $15.48
- VTRS N/A
- Revenue Next Year
- NBIX $16.18
- VTRS $1.19
- P/E Ratio
- NBIX $26.38
- VTRS N/A
- Revenue Growth
- NBIX 24.81
- VTRS N/A
- 52 Week Low
- NBIX $86.58
- VTRS $7.15
- 52 Week High
- NBIX $157.98
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- NBIX 20.83
- VTRS 18.09
- Support Level
- NBIX $113.05
- VTRS $7.15
- Resistance Level
- NBIX $112.74
- VTRS $9.35
- Average True Range (ATR)
- NBIX 3.20
- VTRS 0.35
- MACD
- NBIX -1.46
- VTRS -0.11
- Stochastic Oscillator
- NBIX 4.59
- VTRS 8.90
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.